Article Per Year (5 Year)
p-Index From 2021 - 2026
0.817
P-Index
This Author published in this journals
All Journal Jurnal Cahaya Mandalika Asian Journal of Health Research Folia Medica Indonesiana
Albab, Chabib Fachry
Unknown Affiliation
Humanities Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Medicine & Pharmacology Neuroscience Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Systematic Review & Meta-Analysis Triple Inhaler Therapy Outperforms Dual Therapy in Moderate to Severe COPD: A Meta-Analysis of 11,477 Patients from 4 Randomized Controlled Trials Shows Improved Lung Function, Reduced Exacerbations, and Comparable Safety Profile Albab, Chabib Fachry; Habibah, Almas Talida; Wulandhari; Murteza, Faiq; Mas'udi, Achmad Fayyad
Asian Journal of Health Research Vol. 4 No. 1 (2025): Volume 4 No 1 (April) 2025
Publisher : Ikatan Dokter Indonesia Wilayah Jawa Timur

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55561/ajhr.v4i1.224

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) continues to be one of the most prevalent health conditions globally. Treatment strategies for COPD are often tailored to disease severity, beginning with single therapy and advancing to dual or triple therapy as needed. However, limited randomized controlled trials (RCTs) have explored the comparative impact of dual and triple inhaler therapies on clinical outcomes and exacerbation frequencies. Our meta-analysis aims to evaluate the effectiveness and safety of triple and double medication in moderate and severe COPD patients.    Material and Methods: A comprehensive exploration of databases was conducted to identify RCTs comparing triple and dual inhaler therapies. For binary outcomes, the pooled RR or OR was calculated; we also used weighted MD to analyze continuous outcomes, both with high CI (95%).    Results: The meta-analysis included four RCTs involving 13,574 patients, of whom 67.92% were male. Triple inhaler therapy proves lung function improvements significantly, evidenced by an increase in FEV1 (MD: 0.06; 95% CI: 0.01–0.11; p=0.02). It showed significant association with a exacerbations reduction in both moderate and severe one (RR: 0.76; 95% CI: 0.72–0.81; p<0.000001). No notable differences in adverse events were observed between combination of triple and double medication (OR: 0.99; 95% CI: 0.90–1.10; p=0.85).    Conclusion: Triple inhaler medication proves more effective than double medication in moderate and severe COPD patients, enhancing lung function and lowering exacerbation rates without a significant increase in adverse effects.
THE EFFECT OF ORLISTAT ADMINISTRATION IN HbA1c, WEIGHT LOSS AND FASTING BLOOD GLUCOSE (FBG) OF OBESITY OR OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META ANALYSIS Albab, Chabib Fachry; Habibah, Almas Talida; El-Ma’i, Zaha; Hanifullah, Ardan Mulyarajasa; Permatasari, Azmil
Jurnal Cahaya Mandalika ISSN 2721-4796 (online) Vol. 3 No. 3 (2022)
Publisher : Institut Penelitian Dan Pengambangan Mandalika Indonesia (IP2MI)

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Orlistat has unique mechanism of action in the pharmacological agents for obesity management in patients with type 2 diabetes mellitus (T2DM). This meta-analysis was to consolidate the existing body of evidence regarding the effect of Orlistat administration on HbA1c levels, weight loss, and fasting blood glucose (FBG) levels in patients who are both obese or overweight and diagnosed with T2DM. The method used in this study was systematic review and meta-analysis which literature search was carried out using PubMed and Science Direct. A systematic review of published studies following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 was conducted. The protocol of this review was registered at PROSPERO. There were 9 selected randomized controlled trials with a total of 1935 patients were included. The analysis found there was significantly reduction in HbA1c (Mean differences [MD]: -0.67; 95% CI: -1.10 - -0.23; p = 0.003), weight loss (Mean differences [MD]: -2.85; 95% CI: -3.23 – -2.48; p < 0.00001), and fasting blood glucose (Mean differences [MD]: -1.23; 95% CI: -1.66 – -0.80; p < 0.00001). The conclusion obtained from the analysis that the effect of orlistat administration demonstrates significant reductions in HbA1c, body weight, and fasting blood glucose levels. It may have a benefical intervention for managing T2DM with obesity or overweight.
Impact of SYNTAX Scores on the Long-Term Outcomes of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for Left Main Coronary Artery Disease Murteza, Faiq; Albab, Chabib Fachry; Habibah, Almas Talida; Mas'udi, Achmad Fayyad; Pravitasari, Vemaniarti Lian; Rajanagara, Arya Satya; El-Ma'i, Zaha
Folia Medica Indonesiana Vol. 59, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score was designed to predict the post-procedural risk associated with percutaneous coronary intervention (PCI) or surgical revascularization. This study aimed to evaluate the long-term outcomes of PCI and coronary artery bypass grafting (CABG) by comparing several existing studies. A systematic search was performed using the PubMed (MEDLINE) and ScienceDirect databases. This systematic review included studies that examined differences in the outcomes of PCI and CABG for left main coronary artery (LMCA) stenosis. This was a systematic review study in which we reviewed original cross-sectional and cohort studies. The search was conducted from February 1st until February 2nd, 2023. The quality assessment of the studies was carried out using the criteria outlined in the Newcastle-Ottawa Scale (NOS). According to the final assessment, all the original research included had a mean NOS score of 8, indicating excellent quality. The literature search yielded 1,675 studies, five of which were selected for the final analysis. A total of 5,494 patients underwent PCI and CABG. This study found that there were variations in outcomes among patients with low, medium, and high SYNTAX scores for long-term major adverse cardiac or cerebrovascular events (MACCE) and long-term mortality. However, similar outcomes were observed in long-term revascularization, long-term stroke, and long-term myocardial infarction (MI). This study concluded that patients with LMCA stenosis and SYNTAX scores ranging from low to high may have different long-term outcomes. CABG is associated with a lower incidence of mortality, repeat revascularization, MI, and MACCE compared to PCI. On the other hand, an association exists between PCI and a lower incidence of stroke.
The Effect of Orlistat Administration in Change of Glycemic Control and Weight Loss of Obesity or Overweight Patients with Type 2 Diabetes Mellitus Johan, Abu Rizal Dwikatmono; Dewanti, Linda; Putri, Anandia Nafisah; Pantoro, Benny Iswanto; Albab, Chabib Fachry; Hutauruk, Maria Marind Desrianti; Novitasari, Triana
Folia Medica Indonesiana Vol. 58, No. 1
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Hightlight: • The effect of orlistat on glycemic control and weight loss in overweight or obese type 2 diabetes mellitus patients was determined • HbA1c and FPG level in overweight and obese type 2 diabetes mellitus patient can improved by orlistat as an adjuvant therapy. Abstract: Risk of Type 2 diabetes mellitus (T2DM) increases steadily with increasing overweight and obesity, and these two-health problems are emerging epidemics worldwide. Orlistat, a lipase inhibitor for weight loss drug, is often used in T2DM medication as adjuvant therapy, but effectiveness of the drug for improving glycemic control on T2DM patients is unclear. This study was to determine the effect of orlistat on glycemic control and weight loss in overweight or obese patients with T2DM. Term "Orlistat” AND "(obesity OR overweight)” AND "(HbA1c OR A1C)” AND "diabetes” were systematically searched in Pubmed and Science Direct web databases up to March 2021. Only randomized controlled study (RCT) methods studies were included in this study. Collected final samples were presented in a table with narrative review. There were 9 RCT studies with a total 2,175 subjects that met inclusion criteria. Of the sample, 360 mg/day orlistat as an adjuvant therapy, was administered to overweight or obese T2DM patients together with hypocaloric intake (8 studies) or without hypocaloric intake (1 study) intervention. They were examined for 12-52 weeks. From 2 short-term (12 weeks) studies, one study revealed that orlistat improved HbA1c and fasting plasma glucose (FPG) level significantly, while one study showed no significant effect compared to placebo. Seven other studies (long term observation) had found that orlistat significantly improved HbA1c and FPG level. All studies found that orlistat significantly reduced body weight. As an adjuvant therapy, Orlistat improved HbA1c and FPG level in overweight and obese T2DM patients.
Co-Authors El-Ma'i, Zaha El-Ma’i, Zaha Habibah, Almas Talida Hanifullah, Ardan Mulyarajasa Hutauruk, Maria Marind Desrianti Johan, Abu Rizal Dwikatmono Linda Dewanti Mas'udi, Achmad Fayyad Murteza, Faiq Pantoro, Benny Iswanto Permatasari, Azmil Pravitasari, Vemaniarti Lian Putri, Anandia Nafisah Rajanagara, Arya Satya Triana Novitasari, Triana Wulandhari